Itolizumab, CAS 1116433-11-4

Product Description: Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19[1][2][3].

Applications: COVID-19-anti-virus

Formula: N/A

References: [1]Saavedra D, et al. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Immun Ageing. 2020 Nov 14;17(1):34. /[2]Loganathan S, et al. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020 Sep;20(9):1025-1031. /[3]Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017 Jul-Aug;62(4):418-421. /[4]Freitas RF, et al. Modulation of CD4 T cell function via CD6-targeting. EBioMedicine. 2019 Sep;47:427-435. /[5]Globig AM, et al. High-dimensional profiling reveals Tc17 cell enrichment in active Crohn's disease and identifies a potentially targetable signature. Nat Commun. 2022 Jun 27;13(1):3688. /[6]Bughani U, et al. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. PLoS One. 2017 Jul 3;12(7):e0180088. /[7]Cherie Tracy Ng, et al. Itolizumab As a Potential Therapeutic for the Prevention and Treatment of Graft Vs Host Disease. Blood (2019) 134 (Supplement_1): 5603.

CAS Number: 1116433-11-4

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Infection; Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: CD6

• Artikelnummer: MEXHY-P99252-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99252-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK